Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility

CORONA Remedies Limited, a leading India-focused pharmaceutical company with a strong presence across Women's Healthcare, CardioDiabeto, Pain Management and Urology therapies have received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla in Ahmedabad.

These significant milestones further strengthen CORONA's global manufacturing and quality credentials, reaffirming its commitment to world-class quality systems, scientific excellence, and manufacturing capabilities aligned with international standards.

Achieved with exceptional speed, these accreditations reflect CORONA's strong quality culture, robust compliance framework, and operational excellence, marking a defining step in its journey to become a globally trusted partner in Hormone & other therapies.

Commenting on the same, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited said, "We view this accreditation as a reflection of our unwavering commitment to quality and our philosophy of "One World. One Quality." By adopting uniform global practices, we aim to serve both the Indian market and other regulated/semi-regulated markets from this facility.

Backed by strong scientific expertise, rapidly expanding manufacturing capabilities, and a clear strategic vision, we remain committed to advancing accessible, high-quality healthcare in India while taking our Hormone portfolio to global markets - driven by our belief: "THINK HORMONE… THINK CORONA."

Shares of CORONA Remedies Limited was last trading in BSE at Rs. 1674.90 as compared to the previous close of Rs. 1697.90. The total number of shares traded during the day was 3239 in over 337 trades.

The stock hit an intraday high of Rs. 1714.70 and intraday low of 1667.60. The net turnover during the day was Rs. 5435279.00.

Source : Equity Bulls

Keywords

CORONARemedies INE02ZQ01018 Pharmaceuticals EUGMP ComplianceCertification